{"id":"hib-mency-tt-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Injection site swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability"}]},"_chembl":{"chemblId":"CHEMBL3975020","moleculeType":"Small molecule","molecularWeight":"475.60"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Hib-MenCY-TT is a conjugate vaccine that combines polysaccharide antigens from three bacterial pathogens linked to tetanus toxoid as a carrier protein. This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, resulting in robust antibody production and immunological memory against invasive bacterial infections caused by Hib, meningococcal serogroups C and Y, and tetanus.","oneSentence":"This vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b, Neisseria meningitidis serogroups C and Y, and tetanus toxin.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:02:48.797Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive disease caused by Haemophilus influenzae type b"},{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups C and Y"},{"name":"Prevention of tetanus"}]},"trialDetails":[{"nctId":"NCT00614614","phase":"PHASE3","title":"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-13","conditions":"Infections, Meningococcal","enrollment":1558},{"nctId":"NCT01978093","phase":"PHASE3","title":"Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-01","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":600},{"nctId":"NCT00127855","phase":"PHASE2","title":"Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":409},{"nctId":"NCT00129116","phase":"PHASE2","title":"3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":388},{"nctId":"NCT00129129","phase":"PHASE2","title":"Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-08-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":756},{"nctId":"NCT00289783","phase":"PHASE3","title":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-22","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4441},{"nctId":"NCT00134719","phase":"PHASE2","title":"Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04-11","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":1104},{"nctId":"NCT00345579","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4432},{"nctId":"NCT00359983","phase":"PHASE3","title":"Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":270},{"nctId":"NCT00345683","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4021}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Hib-MenCY-TT vaccine","genericName":"Hib-MenCY-TT vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b, Neisseria meningitidis serogroups C and Y, and tetanus toxin. Used for Prevention of invasive disease caused by Haemophilus influenzae type b, Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups C and Y, Prevention of tetanus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}